Table 2.
Upadacitinib estimated average plasma concentrations over a dosing interval for immediate‐release regimens in BALANCE I and BALANCE II
| Upadacitinib dose | Upadacitinib Cave, ng/mL, median (5th–95th percentile) | |
|---|---|---|
| BALANCE I (Anti‐TNF‐inadequate responders) | BALANCE II (MTX‐inadequate responders) | |
| 3 mg b.i.d. | 9.2 (5.3–15.1) | 9.7 (6.3–14.6) |
| 6 mg b.i.d. | 18.4 (11.9–34.6) | 19.7 (12.7–29.9) |
| 12 mg b.i.d. | 39 (24.4–51) | 40.5 (26.7–68.5) |
| 18 mg b.i.d. | 51.2 (33.1–92.3) | 59.8 (40.7–79.8) |
| 24 mg q.d. | – | 35.9 (23.9–53.2) |
b.i.d., twice daily; Cave, average plasma concentration; q.d., once daily.